

Alpha Galactosidase A - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A8FC2202C13FEN.html>

Date: December 2019

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: A8FC2202C13FEN

Abstracts

Alpha Galactosidase A - Pipeline Review, H2 2019

SUMMARY

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha Galactosidase A - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Alpha-galactosidase is a glycoside hydrolase enzyme encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. Mutations in this gene affect the synthesis and stability of this enzyme which causes Fabry's disease. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 6 respectively. Similarly, the universities portfolio in Unknown stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Fabry Disease.

Furthermore, this report also reviews key players involved in Alpha Galactosidase A

(Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)

The report reviews Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Galactosidase A

(Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Overview

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies

Involved in Therapeutics Development

4D Molecular Therapeutics Inc

Amicus Therapeutics Inc

AVROBIO Inc

Biosidus SA

Chiesi Farmaceutici SpA

Freeline Therapeutics Ltd

Greenovation Biotech GmbH

Moderna Therapeutics Inc

Pharming Group NV

Sangamo Therapeutics Inc

UniQure NV

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles

4D-310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

agalsidase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

agalsidase beta biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMT-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVRRD-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLT-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GLA for Fabry Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GLA for Fabry Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

migalastat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOSS-AGAL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-3630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegunigalsidase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-920 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Products

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Product Development Milestones

Featured News & Press Releases

Nov 27, 2019: Protalix BioTherapeutics hosting key opinion leader meeting on PRX-102 drug candidate for the treatment of Fabry Disease

Nov 18, 2019: Protalix BioTherapeutics and Chiesi Farmaceutici announce successful pre-BLA meeting with FDA for accelerated approval of pegunigalsidase alfa for the treatment of Fabry Disease in the United States

Oct 17, 2019: Protalix BioTherapeutics announces positive 12-month interim data from the BRIDGE phase III open label switch-over study of Pegunigalsidase Alfa for the treatment of Fabry Disease

Sep 25, 2019: Protalix and Chiesi close enrolment in Phase III Fabry disease trial

Sep 12, 2019: Freeline doses patient in first Fabry Disease AAV gene therapy trial globally

Aug 02, 2019: Amicus Therapeutics receives marketing authorization for galafold (migalastat) for fabry disease in Argentina

Jul 15, 2019: AVROBIO announces 87% substrate reduction in first kidney biopsy and additional positive data from clinical trials of AVR-RD-01 investigational gene therapy in

Fabry Disease

Jul 02, 2019: Handok releases Fabry disease treatment

Jun 17, 2019: Protalix Biotherapeutics completes enrollment in the phase III bright clinical trial of Pegunigalsidase Alfa (PRX 102) for the treatment of Fabry disease

Jun 06, 2019: Protalix BioTherapeutics and Chiesi Farmaceutici to apply for accelerated approval of pegunigalsidase alfa for the treatment of Fabry Disease in the United States

May 30, 2019: 4D Molecular Therapeutics announces presentation of preclinical data at the 6th International Update on Fabry Disease and provides clinical update

May 28, 2019: Freeline presents preclinical data and phase 1/2 study design of the FLT190 AAV gene therapy for Fabry Disease

May 02, 2019: uniQure announces new preclinical data on fabry disease in oral presentations at the 22nd ASGCT Annual Meeting

May 01, 2019: Avrobio to incorporate plato platform into FAB-201 Phase II trial

Apr 15, 2019: uniQure to present data on Gene Therapy for Fabry Disease at ASGCT 2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by 4D Molecular Therapeutics Inc, H2 2019

Pipeline by Amicus Therapeutics Inc, H2 2019

Pipeline by AVROBIO Inc, H2 2019

Pipeline by Biosidus SA, H2 2019

Pipeline by Chiesi Farmaceutici SpA, H2 2019

Pipeline by Freeline Therapeutics Ltd, H2 2019

Pipeline by Greenovation Biotech GmbH, H2 2019

Pipeline by Moderna Therapeutics Inc, H2 2019

Pipeline by Pharming Group NV, H2 2019

Pipeline by Sangamo Therapeutics Inc, H2 2019

Pipeline by UniQure NV, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

4D Molecular Therapeutics Inc

Amicus Therapeutics Inc

AVROBIO Inc

Biosidus SA

Chiesi Farmaceutici SpA

Freeline Therapeutics Ltd

Greenovation Biotech GmbH

Moderna Therapeutics Inc

Pharming Group NV

Sangamo Therapeutics Inc

UniQure NV

I would like to order

Product name: Alpha Galactosidase A - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A8FC2202C13FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A8FC2202C13FEN.html>